Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been assigned an average recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $6.63.

A number of brokerages have commented on TSHA. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Chardan Capital restated a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Finally, JMP Securities reiterated a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its stake in Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after acquiring an additional 11,390 shares during the period. Geode Capital Management LLC lifted its stake in Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock valued at $7,163,000 after buying an additional 682,273 shares during the last quarter. Barclays PLC increased its stake in shares of Taysha Gene Therapies by 356.0% in the third quarter. Barclays PLC now owns 247,280 shares of the company's stock valued at $513,000 after purchasing an additional 193,046 shares during the period. LPL Financial LLC bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $104,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies during the fourth quarter worth approximately $8,650,000. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Stock Down 6.0 %

Shares of NASDAQ TSHA traded down $0.16 on Wednesday, hitting $2.43. The company had a trading volume of 1,160,248 shares, compared to its average volume of 2,743,210. The business has a 50 day moving average of $1.59 and a two-hundred day moving average of $1.80. The firm has a market capitalization of $497.26 million, a P/E ratio of 3.87 and a beta of 0.90. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.